US Stock Futures Rise Ahead Of Economic Data

Pre-open movers US stock futures traded higher in early pre-market trade. The services PMI for September will be released at 9:45 a.m. ET, while the ISM non-manufacturing index for September will be released at 10:00 a.m. ET. Futures for the Dow Jones Industrial Average jumped 83 points to 16,460.0, while the Standard & Poor's 500 index futures rose 10 points to 1,953.00. Futures for the Nasdaq 100 index surged 26.12 points to 4,287.38. A Peek Into Global Markets European markets were higher today, with the Spanish Ibex Index gaining 3.16 percent, STOXX Europe 600 Index jumping 2.42 percent and German DAX 30 index gaining 2.23 percent. French CAC 40 Index rose 3.16 percent and London's FTSE 100 Index rose 2.11 percent. In Asian markets, Japan's Nikkei Stock Average rose 1.58 percent, Hong Kong's Hang Seng Index gained 1.62 percent and India's BSE Sensex climbed 2.15 percent. Broker Recommendation Analysts at Goldman Sachs downgraded Viacom, Inc. VIAB from undefined to Neutral and lowered the price target to $46.00. Viacom shares rose 3.50 percent to close at $44.33 on Friday. Breaking news

• Potash Corporation of Saskatchewan (USA) POT announced that it has withdrawn its proposal to negotiate a transaction with K PLUS S AG ADR KPLUY. To read the full news, click here.
• Mercer, a global consulting leader in advancing health, wealth and careers, and a wholly owned subsidiary of Marsh & McLennan Companies, Inc. MMC, today announced the acquisition of Human Resources Business Solutions (HRBS), a provider of career and talent consulting and information services to clients across Asia, with concentrated strength in Hong Kong, Singapore and mainland China. To read the full news, click here.
• Boston Scientific Corporation BSX has received U.S. Food and Drug Administration (FDA) approval for the SYNERGY™ Bioabsorbable Polymer Drug-Eluting Stent System (BP-DES) for the treatment of coronary artery disease. To read the full news, click here.
• Impax Laboratories Inc IPXL today announced that the U.S. Food and Drug Administration (FDA) has approved its generic version of glyburide tablets 1.25 mg, 2.5 mg, and 5 mg. read the full news, click here.